Trial Profile
Pembrolizumab in Association With the Multipeptide Vaccine IMA950 Adjuvanted With Poly-ICLC for Relapsing Glioblastoma: a Randomized Phase I/ II Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 29 Dec 2022
Price :
$35
*
At a glance
- Drugs IMA 950 (Primary) ; Pembrolizumab (Primary) ; Poly ICLC
- Indications Glioblastoma
- Focus Adverse reactions
- 23 Dec 2022 Planned End Date changed from 10 Nov 2023 to 31 Dec 2023.
- 23 Dec 2022 Planned primary completion date changed from 30 Oct 2021 to 31 Dec 2023.
- 23 Dec 2022 Status changed from recruiting to active, no longer recruiting.